Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | January 26, 2026 | January 27, 2026 |
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Director | June 04, 2026 | June 08, 2026 |
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date January 26, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,458 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 37,313 · Balance 84,458 F1: All of the restricted stock will vest on January 26, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on January 26, 2027.
Amylyx Pharmaceuticals, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.31 · Expires 2036-06-03 | Direct | 24,372 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 24,372 · Balance 24,372 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Entrada Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2036-06-10 | Direct | 19,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 16:52 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001689375-26-000034 · wk-form4_1781297526.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 16:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 24,372 | $0.00 Strike: $14.31 | $0.00 |
DisclosureSEC source: 0001193125-26-261647 · ownership.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,372 Underlying: Common Stock · 24,372 shares Expires 2036-06-03 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 20, 2026 Filed May 21, 2026 16:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 5,000 | $5.86 | $29,316.00 |
DisclosureSEC source: 0001689375-26-000030 · wk-form4_1779395488.xml · nonDerivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 37,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-003809 · ownership.xml · nonDerivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,458 F1 · shares: All of the restricted stock will vest on January 26, 2027. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 08:06 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001689375-25-000031 · wk-form4_1749729970.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 11, 2025 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 16:06 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-083709 · ownership.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 16:15 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 10,000 | $3.70 | $37,005.00 |
DisclosureSEC source: 0000950170-25-043849 · ownership.xml · nonDerivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.65 to $3.73. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:37 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-004755 · ownership.xml · nonDerivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,145 F1 · kind: Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e). F2 · shares: All of the restricted stock will vest on January 31, 2026. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 21:10 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 11,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-032393 · ownership.xml · nonDerivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,044 F1 · kind: Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e). F2 · shares: All of the restricted stock will vest on August 13, 2025. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001689375-24-000035 · wk-form4_1718397283.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 13, 2024 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 16:49 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 5,753 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0000950170-24-070797 · ownership.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,753 Underlying: Common Stock · 5,753 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 16:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0000950170-24-032246 · ownership.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-13 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on the first anniversary of the date of grant, and the remaining two-thirds will vest in equal monthly installments over two years, provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director of the Issuer. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 17:17 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0001689375-23-000025 · wf-form4_168064301724542.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-04-04 F1 · derivative.exercise_date: The stock option shall vest in equal monthly installments over three years from the date of grant, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.